Paul T. Morris, MD, FACS, FCCP

Paul T. Morris, MD, FACS, FCCP

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 521-4664

Clinical Member, Translational and Clinical Research, University of Hawaii Cancer Center
Member, Search Committee, Translational and Clinical Research, University of Hawaii Cancer Center
Member, Hawaii Cancer Consortium Executive Committee

Academic Appointment(s):
Assistant Clinical Professor, University of Hawaii Cancer Center, University of Hawaii at Manoa
Assistant Professor of Surgery, John A. Burns School of Medicine, University of Hawaii at Manoa

MD, Georgetown University
Chief Resident and Junior Faculty Associate, Thoracic & Cardiovascular Surgery, M.D. Anderson Cancer Center University of Texas, Houston, TX
Cardio-Thoracic Surgery Resident, Texas Heart Institute, Houston, TX
Clinical Associate, Mount Sinai Medical Center, New York, NY
General Surgery Resident, Mount Sinai Mecial Center, New York, NY

Research Focus

Dr. Morris has been Chief of Surgery at The Queen's Medical Center since 2009. He has had a long-time interest in optimizing ways to prevent and treat cancer. He has been a clinical faculty member of the University of Hawaii Cancer Center since 1995, has served as President of the Hawaii Society of Clinical Oncology, and has chaired the Cancer Committee and Tumor Board conferences at The Queen's Medical Center for many years He is the Co-Principal Investigator of the current Hawaii Minority/Underserved NCI Community Oncology Research Program (NCORP) grant that focuses on minority and medically underserved populations in Hawaii. His team at The Queen's Medical Center works closely with the University of Hawaii Cancer Center and its consortium partners to expand clinical trials and foster translational research that will benefit all cancer patients in the State.

Selected Publications

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M. (2017). BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature, 546:549-553. doi: 10.1038/nature22798.

Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Salim Saad-Jube Z, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H. (2017). HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget, 8:22649-22661.

Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H. (2012). Malignant mesothelioma: Facts, myths and hypotheses. J Cell Physiol, 227: 44-58, Jan. PMCID: PMC3143206.

Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, Pass HI, Yang H. (2011). Ranpirnase interferes with NF-κB pathway and MMP9 activity, inhibiting Malignant Mesothelioma cell invasiveness and xenografts growth. Genes & Cancer, 2:576-84.

Zhang L, Strianese O, Gaudino G, Morris P, Pass HI, Yang H, Nerurkar VR, Bocchetta M, Carbone M. (2010). Tissue tropism of SV40 transformation of human cells: role of the viral regulatory region and of cellular oncogenes. Genes and Cancer, 1:1008-1020, PMCID: PMC3092263.

Publication list via PubMed

Active Grants

P. Morris, Co-Investigator
Pathogenesis of Malignant Mesothelioma
February 2010 to Present

P. Morris, C-PI for Cancer Care Delivery Research
National Cancer Institute Community Oncology Research Program
The NCORP overall goal is to bring cancer clinical trials and cancer care delivery research (CCDR) to people in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.

P. Morris, Principal Investigator
"National Cancer Institute Community Cancer Center Program, Queens Medical Center"
Primary responsibilities: fiscal oversight of a 3.3 million dollar contract from the NCCCP to oversee the implementation of all aspects of a community cancer center program which includes merging private practice physicians into an outpatient hospital setting. A pioneering effort that is being accomplished through design and vision by creating pathways to ensure a successful transition with regard to insurance reimbursement and compliance issues. Acting as liaison during the negotiation of the Conditions of Participation (CoPs), in which the roles of QMC and providers were clarified to fit this new setting. A major goal is to establish a multi-disciplinary care clinic (MDC,) utilizing National Cancer Institute standards through the recruitment of private practice oncology and primary care physicians, as well as QMC co-management and employed physicians, providing each new patient multiple physician consultations, from specialists in medical oncology, radiation oncology and surgical subspecialties. Since April 2010, fifty three physicians have aligned themselves with the MDCs by signing CoPs. Instituted the use of Dragon Dictate in the Cancer Center, to advance EHR and reduce transcription costs from the influx of physician activity in the Cancer Center. Also accountable for collecting data for submission to the NCCCP for their use in determining Pay for Performance and Accountable Care Organization policies for oncology on a national level.
2010 to Present